


In the claims:

1. (currently amended) A method of treating sexual dysfunction due to trauma and/or nerve damage which accompanies a spinal cord injury in an animal, comprising orally administering to an animal in need of such treatment an effective amount of a compound of formula (I):



wherein:

R<sup>1</sup> is H; C<sub>1</sub>-C<sub>3</sub> alkyl; C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl; or C<sub>3</sub>-C<sub>5</sub> cycloalkyl;

R<sup>2</sup> is H; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with C<sub>3</sub>-C<sub>6</sub> cycloalkyl; C<sub>1</sub>-C<sub>3</sub> perfluoroalkyl; or C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with C<sub>3</sub>-C<sub>6</sub> cycloalkyl; C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl; C<sub>3</sub>-C<sub>5</sub> cycloalkyl; C<sub>3</sub>-C<sub>6</sub> alkenyl; or C<sub>3</sub>-C<sub>6</sub> alkynyl;

R<sup>4</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with OH, NR<sup>5</sup>R<sup>6</sup>, CN, CONR<sup>5</sup>R<sup>6</sup> or CO<sub>2</sub>R<sup>7</sup>; C<sub>2</sub>-C<sub>4</sub> alkenyl optionally substituted with CN, CONR<sup>5</sup>R<sup>6</sup> or CO<sub>2</sub>R<sup>7</sup>; C<sub>2</sub>-C<sub>4</sub> alkanoyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; (hydroxy)C<sub>2</sub>-C<sub>4</sub> alkyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; (C<sub>2</sub>-C<sub>3</sub> alkoxy)C<sub>1</sub>-C<sub>2</sub> alkyl optionally substituted with OH or NR<sup>5</sup>R<sup>6</sup>; CONR<sup>5</sup>R<sup>6</sup>; CO<sub>2</sub>R<sup>7</sup>; halo; NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>R<sup>8</sup>; SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl;

*Pl  
Cont*

$R^5$  and  $R^6$  are each independently H or C<sub>1</sub>-C<sub>4</sub> alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N( $R^{11}$ )-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH;

$R^7$  is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

$R^8$  is C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted with  $NR^5R^6$ ;

$R^9$  and  $R^{10}$  together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino or 4-N( $R^{12}$ )-piperazinyl group wherein said group is optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy,  $NR^{13}R^{14}$  or  $CONR^{13}R^{14}$ ;

$R^{11}$  is H; C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted with phenyl; (hydroxy)C<sub>2</sub>-C<sub>3</sub> alkyl; or C<sub>1</sub>-C<sub>4</sub> alkanoyl;


$R^{12}$  is H; C<sub>1</sub>-C<sub>6</sub> alkyl; (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>6</sub> alkyl; (hydroxy)C<sub>2</sub>-C<sub>6</sub> alkyl; ( $R^{13}R^{14}N$ )C<sub>2</sub>-C<sub>6</sub> alkyl; ( $R^{13}R^{14}NOC$ )C<sub>1</sub>-C<sub>6</sub> alkyl;  $CONR^{13}R^{14}$ ;  $CSNR^{13}R^{14}$ ; or  $C(NH)NR^{13}R^{14}$ ; and

$R^{13}$  and  $R^{14}$  are each independently H; C<sub>1</sub>-C<sub>4</sub> alkyl; (C<sub>1</sub>-C<sub>3</sub> alkoxy)C<sub>2</sub>-C<sub>4</sub> alkyl; or (hydroxy)C<sub>2</sub>-C<sub>4</sub> alkyl;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutical composition containing either entity.

2. (original) A method as defined in claim 1, wherein said compound is selected from sildenafil, and pharmaceutically acceptable salts thereof, and the compound having the structure:



and pharmaceutically acceptable salts thereof.

3. (canceled)

4. (canceled)

5. (original) A method of treating sexual dysfunction due to trauma and/or nerve damage which accompanies a spinal cord injury in an animal, comprising orally administering to an animal in need of such treatment an effective amount of sildenafil, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.

6. (original) A method as defined in claim 5, wherein said pharmaceutically acceptable salt is the citrate.

7. (original) A method as defined in claim 1, wherein said animal is male and exhibits essentially no residual erectile function.

8. (original) A method as defined in claim 5, wherein said animal is male and exhibits essentially no residual erectile function.

9. (original) A method as defined in claim 1, wherein said animal is human.

10. (original) A method as defined in claim 5, wherein said animal is human.

---